Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension

Hidefumi Fukunaga, Takayoshi Ohkubo, Makoto Kobayashi, Yuichiro Tamaki, Masahiro Kikuya, Taku Obara, Miwa Nakagawa, Azusa Hara, Kei Asayama, Hirohito Metoki, Ryusuke Inoue, Junichiro Hashimoto, Kazuhito Totsune, Yutaka Imai

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

OBJECTIVE: Cost-effectiveness of hypertension treatment is an important social and medical issue in Western as well as in Eastern countries, including Japan. Home blood pressure (HBP) measurements have a stronger predictive power for cardiovascular events than casual clinic blood pressure (CBP) measurements. Therefore, the introduction of HBP measurement for the diagnosis and treatment of hypertension should lead to a decrease in medical expenditure. This study presents calculations of the cost savings likely to take place when HBP is implemented for newly detected hypertensive subjects in Japan. DESIGN AND METHODS: We estimate the cost savings from the perspective of a Japanese healthcare system. To estimate the costs associated with changing from CBP to HBP measurement as the diagnostic tool, we constructed a simulation model using data from the Ohasama study. These calculations are based on current estimates for cost of treatment, prevalence of white-coat hypertension at baseline, and varying the incidence of new hypertension after the initial screening. RESULTS: When HBP measurement is not incorporated into the diagnostic process, the medical cost is estimated at US$10.89 million per 1000 subjects per 5 years. When HBP measurement is incorporated, the medical cost is estimated at US$9.33 million per 1000 subjects per 5 years. The reductions in medical costs vary from US$674 000 to US$2.51 million per 1000 subjects per 5 years for treatment of hypertension, when sensitivity analysis is performed. CONCLUSIONS: The introduction of HBP measurement for the treatment of hypertension is very useful for reducing medical costs.

Original languageEnglish
Pages (from-to)685-690
Number of pages6
JournalJournal of hypertension
Volume26
Issue number4
DOIs
Publication statusPublished - 2008 Apr 1
Externally publishedYes

Fingerprint

Cost-Benefit Analysis
Blood Pressure
Hypertension
Costs and Cost Analysis
Cost Savings
Japan
White Coat Hypertension
Health Expenditures
Health Care Costs
Therapeutics
Delivery of Health Care
Incidence

Keywords

  • Cost-effectiveness
  • Home blood pressure
  • Ohasama study
  • Whitecoat hypertension

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. / Fukunaga, Hidefumi; Ohkubo, Takayoshi; Kobayashi, Makoto; Tamaki, Yuichiro; Kikuya, Masahiro; Obara, Taku; Nakagawa, Miwa; Hara, Azusa; Asayama, Kei; Metoki, Hirohito; Inoue, Ryusuke; Hashimoto, Junichiro; Totsune, Kazuhito; Imai, Yutaka.

In: Journal of hypertension, Vol. 26, No. 4, 01.04.2008, p. 685-690.

Research output: Contribution to journalArticle

Fukunaga, H, Ohkubo, T, Kobayashi, M, Tamaki, Y, Kikuya, M, Obara, T, Nakagawa, M, Hara, A, Asayama, K, Metoki, H, Inoue, R, Hashimoto, J, Totsune, K & Imai, Y 2008, 'Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension', Journal of hypertension, vol. 26, no. 4, pp. 685-690. https://doi.org/10.1097/HJH.0b013e3282f42285
Fukunaga, Hidefumi ; Ohkubo, Takayoshi ; Kobayashi, Makoto ; Tamaki, Yuichiro ; Kikuya, Masahiro ; Obara, Taku ; Nakagawa, Miwa ; Hara, Azusa ; Asayama, Kei ; Metoki, Hirohito ; Inoue, Ryusuke ; Hashimoto, Junichiro ; Totsune, Kazuhito ; Imai, Yutaka. / Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension. In: Journal of hypertension. 2008 ; Vol. 26, No. 4. pp. 685-690.
@article{cca3de87edf5497a9311b04129f1009f,
title = "Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension",
abstract = "OBJECTIVE: Cost-effectiveness of hypertension treatment is an important social and medical issue in Western as well as in Eastern countries, including Japan. Home blood pressure (HBP) measurements have a stronger predictive power for cardiovascular events than casual clinic blood pressure (CBP) measurements. Therefore, the introduction of HBP measurement for the diagnosis and treatment of hypertension should lead to a decrease in medical expenditure. This study presents calculations of the cost savings likely to take place when HBP is implemented for newly detected hypertensive subjects in Japan. DESIGN AND METHODS: We estimate the cost savings from the perspective of a Japanese healthcare system. To estimate the costs associated with changing from CBP to HBP measurement as the diagnostic tool, we constructed a simulation model using data from the Ohasama study. These calculations are based on current estimates for cost of treatment, prevalence of white-coat hypertension at baseline, and varying the incidence of new hypertension after the initial screening. RESULTS: When HBP measurement is not incorporated into the diagnostic process, the medical cost is estimated at US$10.89 million per 1000 subjects per 5 years. When HBP measurement is incorporated, the medical cost is estimated at US$9.33 million per 1000 subjects per 5 years. The reductions in medical costs vary from US$674 000 to US$2.51 million per 1000 subjects per 5 years for treatment of hypertension, when sensitivity analysis is performed. CONCLUSIONS: The introduction of HBP measurement for the treatment of hypertension is very useful for reducing medical costs.",
keywords = "Cost-effectiveness, Home blood pressure, Ohasama study, Whitecoat hypertension",
author = "Hidefumi Fukunaga and Takayoshi Ohkubo and Makoto Kobayashi and Yuichiro Tamaki and Masahiro Kikuya and Taku Obara and Miwa Nakagawa and Azusa Hara and Kei Asayama and Hirohito Metoki and Ryusuke Inoue and Junichiro Hashimoto and Kazuhito Totsune and Yutaka Imai",
year = "2008",
month = "4",
day = "1",
doi = "10.1097/HJH.0b013e3282f42285",
language = "English",
volume = "26",
pages = "685--690",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cost-effectiveness of the introduction of home blood pressure measurement in patients with office hypertension

AU - Fukunaga, Hidefumi

AU - Ohkubo, Takayoshi

AU - Kobayashi, Makoto

AU - Tamaki, Yuichiro

AU - Kikuya, Masahiro

AU - Obara, Taku

AU - Nakagawa, Miwa

AU - Hara, Azusa

AU - Asayama, Kei

AU - Metoki, Hirohito

AU - Inoue, Ryusuke

AU - Hashimoto, Junichiro

AU - Totsune, Kazuhito

AU - Imai, Yutaka

PY - 2008/4/1

Y1 - 2008/4/1

N2 - OBJECTIVE: Cost-effectiveness of hypertension treatment is an important social and medical issue in Western as well as in Eastern countries, including Japan. Home blood pressure (HBP) measurements have a stronger predictive power for cardiovascular events than casual clinic blood pressure (CBP) measurements. Therefore, the introduction of HBP measurement for the diagnosis and treatment of hypertension should lead to a decrease in medical expenditure. This study presents calculations of the cost savings likely to take place when HBP is implemented for newly detected hypertensive subjects in Japan. DESIGN AND METHODS: We estimate the cost savings from the perspective of a Japanese healthcare system. To estimate the costs associated with changing from CBP to HBP measurement as the diagnostic tool, we constructed a simulation model using data from the Ohasama study. These calculations are based on current estimates for cost of treatment, prevalence of white-coat hypertension at baseline, and varying the incidence of new hypertension after the initial screening. RESULTS: When HBP measurement is not incorporated into the diagnostic process, the medical cost is estimated at US$10.89 million per 1000 subjects per 5 years. When HBP measurement is incorporated, the medical cost is estimated at US$9.33 million per 1000 subjects per 5 years. The reductions in medical costs vary from US$674 000 to US$2.51 million per 1000 subjects per 5 years for treatment of hypertension, when sensitivity analysis is performed. CONCLUSIONS: The introduction of HBP measurement for the treatment of hypertension is very useful for reducing medical costs.

AB - OBJECTIVE: Cost-effectiveness of hypertension treatment is an important social and medical issue in Western as well as in Eastern countries, including Japan. Home blood pressure (HBP) measurements have a stronger predictive power for cardiovascular events than casual clinic blood pressure (CBP) measurements. Therefore, the introduction of HBP measurement for the diagnosis and treatment of hypertension should lead to a decrease in medical expenditure. This study presents calculations of the cost savings likely to take place when HBP is implemented for newly detected hypertensive subjects in Japan. DESIGN AND METHODS: We estimate the cost savings from the perspective of a Japanese healthcare system. To estimate the costs associated with changing from CBP to HBP measurement as the diagnostic tool, we constructed a simulation model using data from the Ohasama study. These calculations are based on current estimates for cost of treatment, prevalence of white-coat hypertension at baseline, and varying the incidence of new hypertension after the initial screening. RESULTS: When HBP measurement is not incorporated into the diagnostic process, the medical cost is estimated at US$10.89 million per 1000 subjects per 5 years. When HBP measurement is incorporated, the medical cost is estimated at US$9.33 million per 1000 subjects per 5 years. The reductions in medical costs vary from US$674 000 to US$2.51 million per 1000 subjects per 5 years for treatment of hypertension, when sensitivity analysis is performed. CONCLUSIONS: The introduction of HBP measurement for the treatment of hypertension is very useful for reducing medical costs.

KW - Cost-effectiveness

KW - Home blood pressure

KW - Ohasama study

KW - Whitecoat hypertension

UR - http://www.scopus.com/inward/record.url?scp=40449084241&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40449084241&partnerID=8YFLogxK

U2 - 10.1097/HJH.0b013e3282f42285

DO - 10.1097/HJH.0b013e3282f42285

M3 - Article

C2 - 18327077

AN - SCOPUS:40449084241

VL - 26

SP - 685

EP - 690

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 4

ER -